Great article, thanks for sharing....it would be great to see Resverlogix getting that kind of exposure....something that breaks down the science and expresses it in more easier to understand layperson terms.

One company getting a lot of virtual ink in that article is Constellation Pharma....another publicly traded development stage biotech.  Constellation isn't yet in Phase 3, and their Mcap is about $350 million USD....so our Cap of about $500 million USD does compare well, but I still think we should be further ahead to reflect how much more advanced we are....years ahead.  

Bring on that Nasdaq listing, but without a reverse split hopefully.